{
    "name": "ferric derisomaltose",
    "comment": "Rx",
    "other_names": [
        "Monoferric"
    ],
    "classes": [
        "Iron Products"
    ],
    "source": "https://reference.medscape.com/drug/monoferric-ferric-derisomaltose-4000055",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Published studies on the use of IV iron products in pregnant women have not reported an association with adverse developmental outcomes; these studies cannot exclude the absence of any drug-related risk during pregnancy because the studies were not designed to assess for the risk of major birth defects",
            "Available data on use in lactating women demonstrate that iron is present in breast milk",
            "Data do not inform the potential exposure of iron for the breastfed child or the effects on milk production",
            "Consider developmental and health benefits of breastfeeding along with the mother’s clinical need for ferric derisomaltose in addition to any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Iron complexes have been reported to be teratogenic and embryocidal in noniron-depleted pregnant animals",
                    "Findings in animals may be due to iron overload and may not be applicable to patients with iron deficiency",
                    "Animal reproduction studies of ferric derisomaltose administered to rats and rabbits during organogenesis caused adverse developmental outcomes including structural abnormalities and embryofetal mortality at doses ~0.09 and 0.4 times the maximum recommended human dose (MRHD) of 1000 mg, respectively, based on body surface area ",
                    "Administered intravenously to pregnant rabbits during organogenesis, from GD7 to GD20, at doses of 11, 25 and 43 mg Fe/kg/day; the dose of 43 mg Fe/kg/day (approximately 0.8 times the MRHD of 1000 mg, based on BSA) resulted in increased maternal mortality, abortion, and premature delivery, and increased postimplantation loss",
                    "Adverse developmental findings at this dose included fetal mortality, reduced fetal weights, and fetal developmental variations and malformations (including domed head, cleft palate, microglossia, hydrocephaly, small brain); fetal malformations and reduced fetal weights were also noted in the 25 mg Fe/kg/day group (approximately 0.5 times the MRHD based on BSA)"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "Untreated iron deficiency anemia in pregnancy is associated with adverse maternal outcomes (eg, postpartum anemia)",
                    "Adverse pregnancy outcomes associated with iron deficiency anemia include increased risk for preterm delivery and low birth weight",
                    "Risks to fetus associated with maternal severe hypersensitivity reactions",
                    "Severe adverse reactions including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction) may occur in pregnant women with parenteral iron products which may cause fetal bradycardia, especially during second and third trimester"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "Untreated iron deficiency anemia in pregnancy is associated with adverse maternal outcomes (eg, postpartum anemia)",
                    "Adverse pregnancy outcomes associated with iron deficiency anemia include increased risk for preterm delivery and low birth weight",
                    "Risks to fetus associated with maternal severe hypersensitivity reactions",
                    "Severe adverse reactions including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction) may occur in pregnant women with parenteral iron products which may cause fetal bradycardia, especially during second and third trimester"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Available data on use in lactating women demonstrate that iron is present in breast milk",
            "Data do not inform the potential exposure of iron for the breastfed child or the effects on milk production",
            "Consider developmental and health benefits of breastfeeding along with the mother’s clinical need for ferric derisomaltose in addition to any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to ferric derisomaltose or any of its components"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, reported",
                "Excessive therapy with parenteral iron can lead to excess iron storage and possibly iatrogenic hemosiderosis or hemochromatosis; monitor hematologic response (hemoglobin and hematocrit) and iron parameters (serum ferritin and transferrin saturation) during therapy; do not administer to patients with iron overload"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Hypophosphatemia",
            "percent": "2"
        },
        {
            "name": "serum phosphate",
            "percent": "3.5"
        },
        {
            "name": "mg",
            "percent": "1.2"
        },
        {
            "name": "dL",
            "percent": "1"
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "nausea and vomiting",
            "percent": null
        },
        {
            "name": "constipation",
            "percent": null
        },
        {
            "name": "diarrhea",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "pyrexia",
            "percent": null
        },
        {
            "name": "chest pain",
            "percent": null
        },
        {
            "name": "chills",
            "percent": null
        },
        {
            "name": "Fishbane reaction",
            "percent": null
        },
        {
            "name": "extravasation",
            "percent": null
        },
        {
            "name": "influenzalike symptoms",
            "percent": null
        },
        {
            "name": "injection site reactions",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Anaphylactic",
            "percent": null
        },
        {
            "name": "anaphylactoid reaction",
            "percent": null
        },
        {
            "name": "hypersensitivity",
            "percent": null
        },
        {
            "name": "Investigations",
            "percent": null
        },
        {
            "name": "Hepatic enzymes increased",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Back pain",
            "percent": null
        },
        {
            "name": "muscle spasms",
            "percent": null
        },
        {
            "name": "arthralgia",
            "percent": null
        },
        {
            "name": "myalgia",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "headache",
            "percent": null
        },
        {
            "name": "paresthesia",
            "percent": null
        },
        {
            "name": "dysgeusia",
            "percent": null
        },
        {
            "name": "seizure",
            "percent": null
        },
        {
            "name": "loss of consciousness",
            "percent": null
        },
        {
            "name": "syncope",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Anxiety",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic",
            "percent": null
        },
        {
            "name": "and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "cough",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "skin discoloration",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "sweating",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "hypotension",
            "percent": null
        },
        {
            "name": "flushing",
            "percent": null
        },
        {
            "name": "phlebitis",
            "percent": null
        },
        {
            "name": "Extravasation at the injection site that may lead to irritation of the skin and potentially long",
            "percent": null
        },
        {
            "name": "lasting brown discoloration at the site of injection has also been reported",
            "percent": null
        }
    ]
}